Embecta Corp.
$6.02-$0.17 (-2.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $202.3M
- P/E
- 2.1x
- EV / EBITDA
- 4.9x
- Revenue
- $1.1B
- Net margin
- 8.8%
- ROCE
- 35.7%
Price chart
Technical chartScreen technicals →This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -6.2%
- 3M
- +10.1%
- 6M
- +96.7%
- 1Y
- Hidden
- 5Y
- Short history
- This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- A period is left blank when the price history is shorter than the period.
52-week range
This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Day change -$0.17 (-2.7%) from $6.19 to $6.02 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in EMBC, bought on each weekday since 2022.
News & filings
What Embecta filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Return on capital employed of 35.7%.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
- This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 58.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $202.3M
- P/E
- 2.1x
- P/B
- -0.3x
- EV / EBITDA
- 4.9x
- EV / Sales
- 1.3x
- P/S
- 0.2x
- 52-week highThis period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
- 52-week lowThis period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
Profitability
- Operating margin
- 27.4%
- Net margin
- 8.8%
- EBITDA margin
- 26.3%
- ROE
- -14.6%
- ROCE
- 35.7%
- ROA
- 8.7%
- Asset turnover
- 0.99
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -3.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -1.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 21.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $182.4M
Solvency
- Current ratio
- 2.41
- Debt / Equity
- -2.20
- Debt / Assets
- 1.31
- CFO / Net profit
- 2.01
- Cash / Market cap
- 111.5%
Where the revenue went
Of every $100 of FY2025 revenue, $9 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $403.6M |
| Revenue | Gross profit | $676.8M |
| Gross profit | Research and development | $37.3M |
| Gross profit | Selling, general and administrative | $332.0M |
| Gross profit | Other operating expenses | $11.1M |
| Gross profit | Operating income | $296.4M |
| Operating income | Pretax income | $136.3M |
| Operating income | Interest and other expense | $160.1M |
| Pretax income | Tax and other | $40.9M |
| Pretax income | Net income | $95.4M |
Revenue and net profit
Revenue fell 3.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $1.1B | $223.6M |
| FY2023 | $1.1B | $70.4M |
| FY2024 | $1.1B | $78.3M |
| FY2025 | $1.1B | $95.4M |
Cash flows
FY2025: $191.7M from operations, $182.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $412.2M | $388.2M |
| FY2023 | $67.7M | $41.2M |
| FY2024 | $35.7M | $19.9M |
| FY2025 | $191.7M | $182.4M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.1B-3.8%1Y
- EBITDA
- $284.3M+47.5%1Y
- Net profit
- $95.4M+21.8%1Y
- Cash from operations
- $191.7M+437.0%1Y
- Free cash flow
- $182.4M+816.6%1Y
- Revenue CAGR, 3Y
- -1.5%
- Net profit CAGR, 3Y
- -24.7%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.1B | $284.3M | $95.4M | $182.4M | -14.6% | -3.8% | +21.8% |
Monthly returns
Month-by-month returns of EMBC across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.1B |
| Current assets | $631.4M |
| Non-current assets | $459.5M |
| Liabilities | $1.7B |
| Current liabilities | $261.5M |
| Non-current liabilities | $1.5B |
| Equity | -$651.2M |
| Paid-in capital | $80.0M |
| Retained earnings | -$445.6M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; EMBC highlighted.
P/E against peers
EMBC trades at 2.1x earnings against a peer median of -5.2x.
Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Embecta Corp.EMBCthis company | $202.3M | 2.1x | -0.3x | -14.6% | 4.9x |
| Atrium Therapeutics, Inc.RNA | $210.4M | -2.7x | 1.0x | -37.0% | 0.7x |
| Accendra Health, Inc.ACH | $202.9M | -0.2x | -0.4x | 238.8% | 9.3x |
| Sanara MedTech Inc.SMTI | $202.7M | -5.4x | 34.1x | -632.5% | 22.7x |
| TriSalus Life Sciences, Inc.TLSI | $202.7M | -5.2x | -6.0x | 115.8% | -6.6x |
| Alector, Inc.ALEC | $201.0M | — | 6.6x | -466.3% | — |
| Nkarta, Inc.NKTX | $198.2M | — | 0.6x | -33.3% | — |
| Anika Therapeutics, Inc.ANIK | $196.8M | -18.1x | 1.4x | -7.6% | -31.1x |
| Lucid Diagnostics Inc.LUCD | $194.6M | — | 17.8x | -645.1% | — |
| Peer median | — | -5.2x | 1.2x | -35.2% | 0.7x |
Year-to-date ROI
EMBC since 1 January, against earlier years.
Historical volatility
EMBC's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 32.6% |
| FY2023 | 20.0% |
| FY2024 | 25.4% |
| FY2025 | 27.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.1B |
| Cost of revenueCost Of Revenue | $403.6M |
| Gross profitGross Profit | $676.8M |
| Operating expensesOperating Expense | $380.4M |
| Research and developmentResearch And Development | $37.3M |
| Selling, general and administrativeSelling General And Administration | $332.0M |
| Other operating expensesOther Operating Expenses | $700.0k |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $10.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $10.4M |
| Amortization | $10.4M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $10.4M |
| Total expensesTotal Expenses | $784.0M |
| Operating incomeOperating Income | $296.4M |
| Interest and other | |
| Pretax incomePretax Income | $136.3M |
| TaxTax Provision | $40.9M |
| Net incomeNet Income | $95.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.1B |
| Current assetsCurrent Assets | $631.4M |
| Non-current assetsTotal Non Current Assets | $459.5M |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.7B |
| Current liabilitiesCurrent Liabilities | $261.5M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.5B |
| EquityTotal Equity Gross Minority Interest | -$651.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $191.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $191.7M |
| Net income, continuing operationsNet Income From Continuing Operations | $95.4M |
| Depreciation and amortisationDepreciation And Amortization | $40.7M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $40.7M |
| Stock-based compensationStock Based Compensation | $31.6M |
| Deferred taxDeferred Tax | $17.6M |
| Deferred income taxDeferred Income Tax | $17.6M |
| Operating gains and lossesOperating Gains Losses | — |
| Asset impairmentAsset Impairment Charge | $10.6M |
| Pension and employee benefit expensePension And Employee Benefit Expense | — |
| Change in working capitalChange In Working Capital | -$23.7M |
| Other non-cash itemsOther Non Cash Items | $19.5M |
| Investing cash flowInvesting Cash Flow | -$9.3M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$9.3M |
| Capital expenditureCapital Expenditure | -$9.3M |
| Capital expenditure (reported)Capital Expenditure Reported | -$9.3M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | -$226.7M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$226.7M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$186.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$186.0M |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$186.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$186.0M |
| Dividends paidCash Dividends Paid | -$35.0M |
| Common dividends paidCommon Stock Dividend Paid | -$35.0M |
| Other financing chargesNet Other Financing Charges | -$5.7M |
| Change in cashChanges In Cash | -$44.3M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -130.0% |
| Cash at the start of the yearBeginning Cash Position | $274.2M |
| Cash at the end of the yearEnd Cash Position | $228.6M |
| Free cash flowFree Cash Flow | $182.4M |
| Supplemental |
Learn while you research
Academy chapters picked for Embecta Corp. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 2.1 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read